1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 3.4. Market Trends 4. Key Insights 4.1 Prevalence of Multiple Sclerosis - For Key Countreis, 2018 4.2 Regulatory Scenario - For Key Countries 4.3 Patent Snapshot 4.4 New Drug Class Launch 4.5 Pipeline Analysis 4.6 Key Industry Developments - Mergers,Acquisitions and Partnerships 5. Global Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026 5.1. Key Findings / Summary 5.2. Market Analysis, Insights and Forecast – By Drug Class 5.2.1 Immunomodulators 5.2.2 Immunosuppressants 5.2.3 Interferons 5.2.4 Others 5.3. Market Analysis, Insights and Forecast – By Route of Administration 5.3.1 Oral 5.3.2 Injection 5.3.2.1 Intramuscular 5.3.2.2 Subcutaneous 5.3.2.3 Intravenous 5.4. Market Analysis, Insights and Forecast – By Distribution Channel 5.4.1 Hospital Pharmacy 5.4.2 Retail Pharmacy 5.4.3 Online Stores 5.5. Market Analysis, Insights and Forecast – By Region 5.5.1 North America 5.5.2 Europe 5.5.3 Asia Pacific 5.5.4 Latin America 5.5.5 Middle East & Africa 6. North America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026 6.1. Key Findings / Summary 6.2. Market Analysis – By Drug Class 6.2.1 Immunomodulators 6.2.2 Immunosuppressants 6.2.3 Interferons 6.2.4 Others 6.3. Market Analysis – By Route of Administration 6.3.1 Oral 6.3.2 Injection 6.3.2.1 Intramuscular 6.3.2.2 Subcutaneous 6.3.2.3 Intravenous 6.4. Market Analysis – By Distribution Channel 6.4.1 Hospital Pharmacy 6.4.2 Retail Pharmacy 6.4.3 Online Stores 6.5. Market Analysis – By Country 6.5.1 U.S. 6.5.2 Canada 7. Europe Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026 7.1. Key Findings / Summary 7.2. Market Analysis – By Drug Class 7.2.1 Immunomodulators 7.2.2 Immunosuppressants 7.2.3 Interferons 7.2.4 Others 7.3. Market Analysis – By Route of Administration 7.3.1 Oral 7.3.2 Injection 7.3.2.1 Intramuscular 7.3.2.2 Subcutaneous 7.3.2.3 Intravenous 7.4. Market Analysis – By Distribution Channel 7.4.1 Hospitals 7.4.2 Retail Pharmacy 7.4.3 Online Stores 7.5. Market Analysis – By Countries/ Sub regions 7.5.1 U.K. 7.5.2 Germany 7.5.3 France 7.5.4 Italy 7.5.5 Spain 7.5.6 Scandinavia 7.5.7 Rest of Europe 8. Asia Pacific Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026 8.1. Key Findings / Summary 8.2. Market Analysis – By Drug Class 8.2.1 Immunomodulators 8.2.2 Immunosuppressants 8.2.3 Interferons 8.2.4 Others 8.3. Market Analysis – By Route of Administration 8.3.1 Oral 8.3.2 Injection 8.3.2.1 Intramuscular 8.3.2.2 Subcutaneous 8.3.2.3 Intravenous 8.4. Market Analysis – By Distribution Channel 8.4.1 Hospitals 8.4.2 Retail Pharmacy 8.4.3 Online Stores 8.5. Market Analysis – By Countries/ Sub regions 8.5.1 Japan 8.5.2 China 8.5.3 India 8.5.4 Australia 8.5.5 Southeast Asia 8.5.6 Rest of Asia Pacific 9. Latin America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026 9.1. Key Findings / Summary 9.2. Market Analysis – By Drug Class 9.2.1 Immunomodulators 9.2.2 Immunosuppressants 9.2.3 Interferons 9.2.4 Others 9.3. Market Analysis – By Route of Administration 9.3.1 Oral 9.3.2 Injection 9.3.2.1 Intramuscular 9.3.2.2 Subcutaneous 9.3.2.3 Intravenous 9.4. Market Analysis – By Distribution Channel 8.4.1 Hospitals 8.4.2 Retail Pharmacy 8.4.3 Online Stores 9.5. Market Analysis – By Countries/ Sub regions 9.5.1 Brazil 9.5.2 Mexico 9.6.3 Rest of Latin America 10. Middle East & Africa Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026 10.1. Key Findings / Summary 10.2. Market Analysis – By Drug Class 10.2.1 Immunomodulators 10.2.2 Immunosuppressants 10.2.3 Interferons 10.2.4 Others 10.3. Market Analysis – By Route of Administration 10.3.1 Oral 10.3.2 Injection 10.3.2.1 Intramuscular 10.3.2.2 Subcutaneous 10.3.2.3 Intravenous 10.4. Market Analysis – By Distribution Channel 10.4.1 Hospitals 10.4.2 Retail Pharmacy 10.4.3 Online Stores 10.5. Market Analysis – By Countries/ Sub regions 10.5.1 South Africa 10.5.2 GCC 10.5.3 Rest of Middle East & Africa 11. Competitive Analysis 11.1. Key Industry Developments 11.2. Global Market Share Analysis (2018) 11.3. Competition Dashboard 11.4. Comparative Analysis – Major Players 11.5. Company Profiles (Overview, Drug Classs &services, SWOT analysis, Recent developments, strategies, financials (based on availability)) 11.5.1 Biogen 11.5.2 Pfizer, Inc. 11.5.3 F.Hoffmann-La Roche Ltd 11.5.4 Merck& Co., Inc. 11.5.5 Novartis AG 11.5.6 Sanofi 11.5.7 Teva Pharmaceutical Industries Ltd. 11.5.8 Other Prominent Players 12. Strategic Recommendations

Biogen Pfizer, Inc. Hoffmann-La Roche Ltd Merck & Co., Inc. Novartis AG Sanofi Teva Pharmaceutical Industries Ltd. Other players